Publicaciones Similares
Biosimilars in Peru
In Peru, it is necessary to implement criteria regarding the nomenclature of biosimilar medicines and the use of identifiers that allow them to be distinguished from the innovative medicine.
Oppotunities for orphan drugs in Latin America
There are ample opportunities for the entry of orphan drugs into the region. The size of the Latin American orphan drug market was USD 14.17 billion in 2021 and it is estimated that it will increase by 7.38% by 2026. Based on the type of drug, the biological sector dominates the orphan drug market for Latin America
Rare Diseases – Orphan drugs- innovative- models of procurement for rare diseases- pricing and reimbursement in Latin America
Orphan drugs used to treat rare diseases have been labeled “orphan drugs” because of their applicability to very small populations, and they respond to public health needs
Why does the Inflation Reduction Act reduce the prices of Pharmaceuticals?
The Inflation Reduction Act (IRA) is used to lower drug prices by imposing extra costs on drug manufacturers that increase their prices above the inflation rate. This forces manufacturers to keep their price increases below the inflation rate to avoid the penalty
Health System in Ecuador
The Ministry of Public Health (MSP) offers health care services to the entire population.
Biosimilars
It is a biological medicine that contains a
version of the active ingredient of an original biological product (reference product) whose patent has expired.